Lysophosphatidic acid counteracts glucagon-induced hepatocyte glucose production via STAT3

Hepatic glucose production (HGP) is required to maintain normoglycemia during fasting. Glucagon is the primary hormone responsible for increasing HGP; however, there are many additional hormone and metabolic factors that influence glucagon sensitivity. In this study we report that the bioactive lipid lysophosphatidic acid (LPA) regulates hepatocyte glucose production by antagonizing glucagon-induced expression of the gluconeogenic enzyme phosphoenolpyruvate carboxykinase (PEPCK). Treatment of primary hepatocytes with exogenous LPA blunted glucagon-induced PEPCK expression and glucose production. Similarly, knockout mice lacking the LPA-degrading enzyme phospholipid phosphate phosphatase type 1 (PLPP1) had a 2-fold increase in endogenous LPA levels, reduced PEPCK levels during fasting, and decreased hepatic gluconeogenesis in response to a pyruvate challenge. Mechanistically, LPA antagonized glucagon-mediated inhibition of STAT3, a transcriptional repressor of PEPCK. Importantly, LPA did not blunt glucagon-stimulated glucose production or PEPCK expression in hepatocytes lacking STAT3. These data identify a novel role for PLPP1 activity and hepatocyte LPA levels in glucagon sensitivity via a mechanism involving STAT3.

[1]  S. Murase.  Signal Transducer and Activator of Transcription 3 (STAT3) Degradation by Proteasome Controls a Developmental Switch in Neurotrophin Dependence* , 2013, The Journal of Biological Chemistry.

[2]  Bernard P. Kok,et al.  Unlike two peas in a pod: lipid phosphate phosphatases and phosphatidate phosphatases. , 2012, Chemical reviews.

[3]  K. Parsa,et al.  ERK2-Mediated Phosphorylation of Transcriptional Coactivator Binding Protein PIMT/NCoA6IP at Ser298 Augments Hepatic Gluconeogenesis , 2013, PloS one.

[4]  Y. Xiong,et al.  Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. , 2011, Molecular cell.

[5]  M. Dietrich,et al.  STAT3 inhibition of gluconeogenesis is downregulated by SirT1 , 2009, Nature Cell Biology.

[6]  J. Xu,et al.  Lipid Phosphate Phosphatase‐1 in the Regulation of Lysophosphatidate Signaling , 2000, Annals of the New York Academy of Sciences.

[7]  M. Birnbaum,et al.  Hepatic Insulin Signaling is Dispensable for Suppression of Glucose Output by Insulin in Vivo , 2015, Nature Communications.

[8]  A. Garg,et al.  Hepatic Gluconeogenesis Is Enhanced by Phosphatidic Acid Which Remains Uninhibited by Insulin in Lipodystrophic Agpat2−/− Mice* , 2014, The Journal of Biological Chemistry.

[9]  M. Tremblay,et al.  T-Cell Protein Tyrosine Phosphatase Attenuates STAT3 and Insulin Signaling in the Liver to Regulate Gluconeogenesis , 2010, Diabetes.

[10]  W. Röling,et al.  Resilience of Soil Microbial Communities to Metals and Additional Stressors: DNA-Based Approaches for Assessing “Stress-on-Stress” Responses , 2016, International journal of molecular sciences.

[11]  A. Cherrington,et al.  Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. , 2012, The Journal of clinical investigation.

[12]  R. Heine,et al.  Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy , 2006, Diabetologia.

[13]  A. Morris,et al.  Integral membrane lipid phosphatases/phosphotransferases: common structure and diverse functions. , 2005, The Biochemical journal.

[14]  V. Natarajan,et al.  Lipid phosphate phosphohydrolase type 1 (LPP1) degrades extracellular lysophosphatidic acid in vivo. , 2009, The Biochemical journal.

[15]  J. C. Hinshaw,et al.  Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARγ agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Hollenberg,et al.  STAT3 targets the regulatory regions of gluconeogenic genes in vivo. , 2009, Molecular endocrinology.

[17]  L. Baudhuin,et al.  Akt activation induced by lysophosphatidic acid and sphingosine-1-phosphate requires both mitogen-activated protein kinase kinase and p38 mitogen-activated protein kinase and is cell-line specific. , 2002, Molecular pharmacology.

[18]  K. Mikoshiba,et al.  The inositol 1,4,5-trisphosphate receptor. , 1992, Ciba Foundation symposium.

[19]  D. Accili,et al.  Hormonal regulation of hepatic glucose production in health and disease. , 2011, Cell metabolism.

[20]  P. Puigserver,et al.  Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylationa , 2014, Molecular metabolism.

[21]  E. Goetzl,et al.  Modulation of Pro-inflammatory Gene Expression by Nuclear Lysophosphatidic Acid Receptor Type-1* , 2003, Journal of Biological Chemistry.

[22]  M. Prentki,et al.  Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice , 2013, Diabetologia.

[23]  P. Valet,et al.  Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid , 2011, Journal of Lipid Research.

[24]  K. Lynch,et al.  Decreased Peritoneal Ovarian Cancer Growth in Mice Lacking Expression of Lipid Phosphate Phosphohydrolase 1 , 2015, PloS one.

[25]  D. Herr,et al.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. , 2010, Prostaglandins & other lipid mediators.

[26]  Kyoko Noguchi,et al.  LPA receptors: subtypes and biological actions. , 2010, Annual review of pharmacology and toxicology.

[27]  J. Yates,et al.  Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity. , 2012, Cell metabolism.

[28]  T. Helleday,et al.  Lysophosphatidic acid receptor (LPAR) modulators: The current pharmacological toolbox. , 2015, Progress in lipid research.

[29]  A. Morris,et al.  Roles of lysophosphatidic acid in cardiovascular physiology and disease. , 2008, Biochimica et biophysica acta.

[30]  S. Ni,et al.  Analysis of Adenovirus Sequestration in the Liver, Transduction of Hepatic Cells, and Innate Toxicity after Injection of Fiber-Modified Vectors , 2004, Journal of Virology.

[31]  D. Rader,et al.  Tribbles-1 regulates hepatic lipogenesis through posttranscriptional regulation of C/EBPα. , 2015, The Journal of clinical investigation.

[32]  D. James,et al.  Opening of the mitochondrial permeability transition pore links mitochondrial dysfunction to insulin resistance in skeletal muscle. , 2014, Molecular metabolism.

[33]  M. Greenwood,et al.  Lysophosphatidic acid mediates pleiotropic responses in skeletal muscle cells. , 2005, Biochemical and biophysical research communications.

[34]  R. Evans,et al.  A subcutaneous adipose tissue–liver signalling axis controls hepatic gluconeogenesis , 2015, Nature Communications.

[35]  B. Zinman,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.

[36]  Mark A. Burgman,et al.  Scientific Foundations for an IUCN Red List of Ecosystems , 2013, PloS one.

[37]  S. Jitrapakdee.  Transcription factors and coactivators controlling nutrient and hormonal regulation of hepatic gluconeogenesis. , 2012, The international journal of biochemistry & cell biology.

[38]  Ying Huang,et al.  G-Protein-Coupled Lysophosphatidic Acid Receptors and Their Regulation of AKT Signaling , 2016, International journal of molecular sciences.

[39]  G. Opdenakker,et al.  Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy , 2013, Acta Diabetologica.

[40]  J. Chun,et al.  Lysophosphatidic Acid Signaling Protects Pulmonary Vasculature From Hypoxia-Induced Remodeling , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[41]  M. Olianas,et al.  Antidepressants activate the lysophosphatidic acid receptor LPA(1) to induce insulin-like growth factor-I receptor transactivation, stimulation of ERK1/2 signaling and cell proliferation in CHO-K1 fibroblasts. , 2015, Biochemical pharmacology.

[42]  David E James,et al.  IRS1-independent defects define major nodes of insulin resistance. , 2008, Cell metabolism.

[43]  D. Brindley,et al.  Lipid phosphate phosphatases and signaling The work was supported by the Canadian Institutes of Health Research. Published, JLR Papers in Press, December 9, 2008. , 2009, Journal of Lipid Research.

[44]  Y. Kido,et al.  Endoplasmic Reticulum Stress Inhibits STAT3-Dependent Suppression of Hepatic Gluconeogenesis via Dephosphorylation and Deacetylation , 2011, Diabetes.

[45]  Kristopher J. Stanya,et al.  Direct control of hepatic glucose production by interleukin-13 in mice. , 2013, The Journal of clinical investigation.

[46]  K. Park,et al.  Lysophosphatidic acid regulates blood glucose by stimulating myotube and adipocyte glucose uptake , 2008, Journal of Molecular Medicine.

[47]  Y. Kido,et al.  Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo , 2004, Nature Medicine.

[48]  A. Subramanian,et al.  Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. , 2016, Cancer cell.

[49]  Yaohui Nie,et al.  MAPK phosphatase-3 promotes hepatic gluconeogenesis through dephosphorylation of forkhead box O1 in mice. , 2010, The Journal of clinical investigation.

[50]  Jacob H. Swet,et al.  Altered lysophosphatidic acid (LPA) receptor expression during hepatic regeneration in a mouse model of partial hepatectomy. , 2014, HPB : the official journal of the International Hepato Pancreato Biliary Association.